253 related articles for article (PubMed ID: 24810241)
1. Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug.
Alam MI; Baboota S; Ahuja A; Ali M; Ali J; Sahni JK; Bhatnagar A
Int J Pharm; 2014 Aug; 470(1-2):99-106. PubMed ID: 24810241
[TBL] [Abstract][Full Text] [Related]
2. Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood.
Alam MI; Baboota S; Ahuja A; Ali M; Ali J; Sahni JK
Drug Deliv; 2013 Aug; 20(6):247-51. PubMed ID: 23869788
[TBL] [Abstract][Full Text] [Related]
3. Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain.
Alam MI; Baboota S; Ahuja A; Ali M; Ali J; Sahni JK
J Psychiatr Res; 2012 Sep; 46(9):1133-8. PubMed ID: 22749490
[TBL] [Abstract][Full Text] [Related]
4. Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: preparation, optimization, characterization and pharmacokinetic evaluation.
Masjedi M; Azadi A; Heidari R; Mohammadi-Samani S
J Pharm Pharmacol; 2020 Oct; 72(10):1341-1351. PubMed ID: 32579251
[TBL] [Abstract][Full Text] [Related]
5. Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies.
Elsenosy FM; Abdelbary GA; Elshafeey AH; Elsayed I; Fares AR
Int J Nanomedicine; 2020; 15():9517-9537. PubMed ID: 33324051
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam.
Abdel-Bar HM; Abdel-Reheem AY; Awad GA; Mortada ND
J Pharm Pharm Sci; 2013; 16(3):456-69. PubMed ID: 24021293
[TBL] [Abstract][Full Text] [Related]
7. A coupled bimodal SPECT-CT imaging and brain kinetics studies of zolmitriptan-encapsulated nanostructured polymeric carriers.
Mandlik SK; Ranpise NS; Mohanty BS; Chaudhari PR
Drug Deliv Transl Res; 2018 Jun; 8(3):797-805. PubMed ID: 29380155
[TBL] [Abstract][Full Text] [Related]
8. Agranulocytosis-Protective Olanzapine-Loaded Nanostructured Lipid Carriers Engineered for CNS Delivery: Optimization and Hematological Toxicity Studies.
Gadhave DG; Tagalpallewar AA; Kokare CR
AAPS PharmSciTech; 2019 Jan; 20(1):22. PubMed ID: 30604305
[TBL] [Abstract][Full Text] [Related]
9. Optimization of artemether-loaded NLC for intranasal delivery using central composite design.
Jain K; Sood S; Gowthamarajan K
Drug Deliv; 2015; 22(7):940-54. PubMed ID: 24512368
[TBL] [Abstract][Full Text] [Related]
10. Nose-to-brain delivery of tacrine.
Jogani VV; Shah PJ; Mishra P; Mishra AK; Misra AR
J Pharm Pharmacol; 2007 Sep; 59(9):1199-205. PubMed ID: 17883890
[TBL] [Abstract][Full Text] [Related]
11. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration.
Gartziandia O; Herran E; Pedraz JL; Carro E; Igartua M; Hernandez RM
Colloids Surf B Biointerfaces; 2015 Oct; 134():304-13. PubMed ID: 26209963
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats.
Zakarial Ansar FH; Latifah SY; Wan Kamal WHB; Khong KC; Ng Y; Foong JN; Gopalsamy B; Ng WK; How CW; Ong YS; Abdullah R; Aziz MY
Int J Nanomedicine; 2020; 15():7703-7717. PubMed ID: 33116496
[TBL] [Abstract][Full Text] [Related]
13. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies.
Gadhave DG; Kokare CR
Drug Dev Ind Pharm; 2019 May; 45(5):839-851. PubMed ID: 30702966
[TBL] [Abstract][Full Text] [Related]
14. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation.
Liu X; Zhang Z; Jiang Y; Hu Y; Wang Z; Liu J; Feng R; Zhang J; Huang G
Drug Deliv; 2015 Feb; 22(2):223-9. PubMed ID: 24559497
[TBL] [Abstract][Full Text] [Related]
15. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease.
Muntimadugu E; Dhommati R; Jain A; Challa VG; Shaheen M; Khan W
Eur J Pharm Sci; 2016 Sep; 92():224-34. PubMed ID: 27185298
[TBL] [Abstract][Full Text] [Related]
16. Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease.
Mishra N; Sharma S; Deshmukh R; Kumar A; Sharma R
Cent Nerv Syst Agents Med Chem; 2019; 19(1):46-56. PubMed ID: 30474538
[TBL] [Abstract][Full Text] [Related]
17. Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: In-vivo pharmacokinetic and toxicity study.
Pokharkar V; Patil-Gadhe A; Palla P
Biomed Pharmacother; 2017 Oct; 94():150-164. PubMed ID: 28759752
[TBL] [Abstract][Full Text] [Related]
18. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats.
Khan S; Patil K; Bobade N; Yeole P; Gaikwad R
J Drug Target; 2010 Apr; 18(3):223-34. PubMed ID: 20030503
[TBL] [Abstract][Full Text] [Related]
19. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route.
Gabal YM; Kamel AO; Sammour OA; Elshafeey AH
Int J Pharm; 2014 Oct; 473(1-2):442-57. PubMed ID: 25062866
[TBL] [Abstract][Full Text] [Related]
20. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.
Mahajan HS; Mahajan MS; Nerkar PP; Agrawal A
Drug Deliv; 2014 Mar; 21(2):148-54. PubMed ID: 24128122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
